Oppenheimer assumed coverage on shares of bluebird bio (NASDAQ:BLUE) in a report released on Wednesday morning. The firm issued a market perform rating on the biotechnology company’s stock.

Other equities analysts also recently issued reports about the company. Maxim Group restated a buy rating and issued a $170.00 price objective (up from $100.00) on shares of bluebird bio in a research report on Monday, October 9th. Wells Fargo & Company reaffirmed an outperform rating and issued a $158.00 target price (up from $134.00) on shares of bluebird bio in a report on Tuesday, September 5th. Morgan Stanley cut bluebird bio from an equal weight rating to an underweight rating and set a $105.00 target price on the stock. in a report on Monday, October 2nd. Barclays assumed coverage on bluebird bio in a report on Wednesday, September 6th. They issued an overweight rating and a $151.00 target price on the stock. Finally, Jefferies Group reaffirmed a hold rating and issued a $130.00 target price on shares of bluebird bio in a report on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $157.45.

Shares of bluebird bio (NASDAQ BLUE) traded up $3.15 during trading on Wednesday, hitting $185.25. The stock had a trading volume of 397,500 shares, compared to its average volume of 867,129. bluebird bio has a fifty-two week low of $60.95 and a fifty-two week high of $222.03.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The business had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. During the same quarter in the previous year, the firm earned ($2.07) earnings per share. bluebird bio’s revenue was up 397.4% on a year-over-year basis. sell-side analysts predict that bluebird bio will post -6.7 EPS for the current fiscal year.

In other bluebird bio news, COO Susanna Gatti High sold 1,282 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $172.15, for a total transaction of $220,696.30. Following the sale, the chief operating officer now directly owns 13,718 shares of the company’s stock, valued at $2,361,553.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Nick Leschly sold 10,823 shares of the business’s stock in a transaction that occurred on Tuesday, October 17th. The stock was sold at an average price of $145.05, for a total value of $1,569,876.15. Following the sale, the chief executive officer now directly owns 262,409 shares in the company, valued at $38,062,425.45. The disclosure for this sale can be found here. Insiders have sold 215,082 shares of company stock worth $37,227,332 over the last three months. 3.90% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in BLUE. QS Investors LLC grew its stake in shares of bluebird bio by 70.7% during the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 500 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of bluebird bio by 454.2% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 813 shares during the last quarter. Bank of Montreal Can grew its stake in shares of bluebird bio by 118.9% during the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 911 shares during the last quarter. Turner Investments LLC bought a new position in shares of bluebird bio during the second quarter valued at approximately $184,000. Finally, Biondo Investment Advisors LLC bought a new position in shares of bluebird bio during the third quarter valued at approximately $203,000.

TRADEMARK VIOLATION NOTICE: “bluebird bio (BLUE) Receives New Coverage from Analysts at Oppenheimer” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/bluebird-bio-blue-receives-new-coverage-from-analysts-at-oppenheimer/1776478.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.